Largest B2C integrated pathology-radiology diagnostic chain in India; 162 centres, hub-and-spoke model
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 270 | 354 | 458 | 535 | 647 | 785 | 855 | 947 |
| Borrowings | 161 | 141 | 183 | 248 | 259 | 320 | 365 | 423 |
| Other Liabilities | 46 | 41 | 62 | 61 | 66 | 158 | 160 | 127 |
| Total Liabilities | 482 | 541 | 713 | 853 | 983 | 1.3k | 1.4k | 1.5k |
| AssetsFixed Assets | 272 | 268 | 370 | 524 | 742 | 865 | 984 | 1.1k |
| CWIP | 10 | 9 | 34 | 28 | 9 | 70 | 45 | 34 |
| Investments | 55 | 28 | 54 | 139 | 109 | 185 | 229 | 228 |
| Other Assets | 146 | 236 | 255 | 163 | 123 | 154 | 133 | 174 |
| Total Assets | 482 | 541 | 713 | 853 | 983 | 1.3k | 1.4k | 1.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 91 | 106 | 130 | 158 | 165 | 183 | 224 | 271 |
| Cash from Investing | -90 | -31 | -130 | -123 | -110 | -141 | -182 | -174 |
| Cash from Financing | -7 | -30 | -49 | -31 | -42 | -45 | -52 | -69 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 31 | 69 | 98 | 37 | 40 | 99 | 132 | 91 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (61.8×) and current (79.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 26.7% growth and a 62× exit, ₹1341 only delivers your return if you pay ₹1,580. The price is currently baking in 23% growth.
EPS grows 26.7%/yr for 5 years, then fades to 6% over 2, exits at 62×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 26.7% | 21.32 |
| FY28 | 26.7% | 27.02 |
| FY29 | 26.7% | 34.23 |
| FY30 | 26.7% | 43.37 |
| FY31 | 26.7% | 54.95 |
| FY32 | 16.4% ·fade | 63.93 |
| FY33 | 6.0% ·fade | 67.77 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.